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Summary
Background—Multidrug-resistant (MDR) tuberculosis is a potential threat to tuberculosis 
elimination, but the extent of MDR tuberculosis disease in the USA that is attributable to 
transmission within the country is unknown. We assessed transmission of MDR tuberculosis and 
potential contributing factors in the USA.
Methods—In a cross-sectional study, clinical, demographic, epidemiological, and 
Mycobacterium tuberculosis genotype data were obtained during routine surveillance of all 
verified cases of MDR tuberculosis reported from eight states in the USA (California from Jan 1, 
2007, to Dec 31, 2009; Texas from Jan 1, 2007, to March 31, 2009; and the states of Colorado, 
Maryland, Massachusetts, New York, Tennessee, and Washington from Jan 1, 2007 to Dec 31, 
2008). In-depth interviews and health-record abstraction were done for all who consented to 
ascertain potential interpersonal connections.
Findings—168 cases of MDR tuberculosis were reported in the eight states during our study 
period. 92 individuals (55%) consented to in-depth interview. 20 (22%) of these individuals 
developed MDR tuberculosis as a result of transmission in the USA; a source case was identified 
for eight of them (9%). 20 individuals (22%) had imported active tuberculosis (ie, culture-
confirmed disease within 3 months of entry into the USA). 38 (41%) were deemed to have 
reactivation of disease, of whom 14 (15%) had a known previous episode of tuberculosis outside 
the USA. Five individuals (5%) had documented treatment of a previous episode in the USA, and 
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so were deemed to have relapsed. For nine cases (10%), insufficient evidence was available to 
definitively classify reason for presentation.
Interpretation—About a fifth of cases of MDR tuberculosis in the USA can be linked to 
transmission within the country. Many individuals acquire MDR tuberculosis before entry into the 
USA. MDR tuberculosis needs to be diagnosed rapidly to reduce potential infectious periods, and 
clinicians should consider latent tuberculosis infection treatment—tailored to the results of drug 
susceptibility testing of the putative source case—for exposed individuals.
Funding—Centers for Disease Control and Prevention.
Introduction
Drug-resistant tuberculosis is a major public health problem worldwide.1–5 WHO estimates 
that more than 650 000 cases of multidrug-resistant (MDR) tuberculosis—defined as 
Mycobacterium tuberculosis resistant to at least isoniazid and rifampicin—emerge globally 
every year.6 The development of drug resistance can be attributed to several factors, such as 
poor adherence to treatment, inadequate clinical management, drug malabsorption, and 
unstable drug supply.7 Person-to-person transmission of MDR tuberculosis could be further 
fuelled by slow bacteriological conversion, delayed diagnosis and initiation of MDR-
specific treatment, and treatment failure, as suggested by widespread outbreaks and 
secondary transmission of MDR tuberculosis within individual households and 
communities.8–10 Migration of foreign-born individuals from areas with a high burden of 
MDR tuberculosis to those with a low burden could be an important factor.11–13 A multiyear 
study of all cases of MDR tuberculosis reported in California, USA, showed that 92% were 
foreign-born individuals.14
MDR tuberculosis has a substantial economic effect on programmatic activities, which is a 
result of treatment costs of long regimens, frequent admissions to hospital, and the necessary 
use of injectable drugs.15 Although some control programmes have successfully reduced 
transmission of MDR tuberculosis,16–18 the extent of MDR tuberculosis attributable to 
transmission in the USA is unknown. Previous studies14,17,18 have not had wide 
geographical scopes or in-depth examination of epidemiological and clinical information 
that is necessary to confirm transmission. In this study, we analysed M tuberculosis 
genotyping data and interpersonal connections between cases of MDR tuberculosis to assess 
potential factors contributing to transmission in eight US states.
Methods
Study population
This cross-sectional study was undertaken by the Tuberculosis Epidemiologic Studies 
Consortium (TBESC).19 It included all verified cases of MDR tuberculosis reported to the 
US National Tuberculosis Surveillance System (NTSS) and National Tuberculosis 
Genotyping Service (NTGS) from eight states: California from Jan 1, 2007, to Dec 31, 2009; 
Texas from Jan 1, 2007, to March 31, 2009; and Colorado, Maryland, Massachusetts, New 
York, Tennessee, and Washington from Jan 1, 2007 to Dec 31, 2008. Study periods were 
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staggered because of delays in study approval in several sites and extended funding in 
California.
The institutional review boards of the Centers for Disease Control and Prevention (CDC) 
and all participating institutions19 approved the study. All interviewed participants gave 
written informed consent.
Procedures
Clinical, demographic, epidemiological, and M tuberculosis genotype variables for each 
case were obtained during routine surveillance, as described elsewhere.20 Additionally, for 
all individuals who gave consent, interviews (with a structured and standardised face-to-face 
questionnaire) and health-record abstraction were done by trained study staff to ascertain 
potential interpersonal connections (appendix). Health records were hospital-based medical 
records and public health records, which included contact investigation logs.
We defined drug resistance as any resistance on a drug susceptibility test (DST) reported to 
NTSS or identified during health-record abstraction. Results from conventional DST (ie, 
liquid-based or agar-based media) were used for NTSS reporting. Results of rapid drug-
resistance tests (ie, molecular beacon, line probe assay, or other molecular test) were not 
included.
Isolates of the M tuberculosis complex were characterised with a standardised protocol for 
spacer oligonucleotide typing (spoligotyping), mycobacterial interspersed repetitive-unit–
variable-number tandem-repeat (MIRU–VNTR) genotyping, and IS6110 restriction 
fragment length polymorphism (IS6110-RFLP) analysis as part of routine molecular 
surveillance at two contract laboratories with documented quality of performance and 
reproducibility.20,21 For the purposes of this study, a genotype was defined as a discrete 
combination of spoligotype and 12-locus MIRU-VNTR results (ie, an exact match on all 
loci). When available, extended typing methods, 24-locus MIRU-VNTR, or IS6110-RFLP 
fingerprinting, or any combination of the three, were done to increase specificity.21
We defined genotype clusters as at least two cases of MDR tuberculosis, of which at least 
one was a study case, that had matching genotypes in a specific TBESC state between Jan 1, 
2005, and June 30, 2011 (surveillance period). We created the surveillance period to allow 
sufficient time to estimate recent transmission within genotype clusters and to include 
potential transmission events with non-study cases. When extended typing methods were 
available, we defined genotype clusters as at least two cases of MDR tuberculosis with 
matching genotype and extended method data (ie, exact match on all 24-loci MIRU-VNTR 
or IS6110-RFLP patterns). Study cases with no matching genotype, or, when applicable, 
with matching genotype but different extended typing results, were deemed to be non-
clustered. A conservative approach to definition of genotype clusters was taken, because 
nationally defined cluster proportions were shown to be greater than 75% in other 
studies.22,23
We defined epidemiological links as named contacts or shared transmission venues 
identified during interview or documented as part of standardised tuberculosis contact 
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investigation activities.24 Briefly, contact investigations are multistep processes, in which 
contacts are systematically assessed on the basis of the amount of time spent with the 
infectious person, the environmental conditions of the transmission venue, and the host 
susceptibility to tuberculosis infection in individuals who are in close contact.24,25 Although 
genotype cluster definitions were based on state, the same strain could be in several states, 
and we applied no restriction for documentation of transmission occurring between states or 
set by arbitrary periods through epidemiological links.
We defined an index case as the first case of tuberculosis identified in a genotype cluster by 
case date (eg, earliest count date, treatment start date, or report date). Spoligotype and 12-
locus MIRU-VNTR results were used to assign phylogenetic lineage, as described 
elsewhere.26 To establish the likelihood of transmission in the USA, we classified cases on 
the basis of genotype, report date, and epidemiological link. Unlikely transmission was 
defined as cases of MDR tuberculosis with non-clustered genotypes reported in the same 
state (with or without extended typing data), and no epidemiological link. Possible 
transmission was defined as study cases for which at least one other case of MDR 
tuberculosis with matching genotype (with or without extended typing data) had been 
reported in the same state, but with no epidemiological link. Definite transmission was 
defined as study cases with at least one other case of MDR tuberculosis with matching 
genotype (with or without extended typing data) and an epidemiological link. To classify the 
reason for disease occurrence, we developed seven categories (table 1).
Statistical analyses
We compared the distribution of clinical, demographic, and epidemiological characteristics 
of clustered and non-clustered cases of MDR tuberculosis with differences of proportion, as 
assessed by Pearson’s χ2 or Fisher’s exact test when the cell count was less than five. We 
used the Shapiro-Wilk test to test for normality. Unless otherwise specified, we used median 
values with IQRs as a measure of central tendency to avoid extreme values. We used 
relative risk and 95% CIs to assess the association of specific variables with the outcome of 
tuberculosis transmission. We used SAS (version 9.3) for all analyses.
Role of the funding source
The CDC Division of Tuberculosis Elimination and the TBESC led study design, training 
for data collection and monitoring, data analysis, data interpretation, and writing of the 
report. The corresponding author had full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
During the study periods, 29 050 verified cases of tuberculosis were reported in the USA. Of 
these, 22 725 (78%) were culture positive, including 22 222 (76%) with DST results for 
isoniazid and rifampicin. Of individuals with reported DST results, 268 (1%) had MDR 
tuberculosis. 168 (63%) of these individuals with MDR disease were reported from the eight 
study sites, of whom 92 (55%) consented to an in-depth interview. For the other 76 (45%), 
analysis was limited to routinely obtained surveillance variables.
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Individuals who were members of genotype clusters were more likely to be male 
(p<0·0001), be Hispanic (p<0·0001), be in prison at time of diagnosis (p=0·01), and have an 
M tuberculosis isolate of Euro-American lineage (p=0·004) than were non-members (table 
2). 144 individuals (86%) with MDR tuberculosis were born outside of the USA, but the 
proportion of individuals born outside the USA who were or were not members of clusters 
did not differ significantly (p=0·53; table 2). Additionally, we recorded no significant 
differences in clinical characteristics—the proportion with a positive sputum smear 
(p=0·77), pulmonary disease (p=0·37), or cavitation on chest radiography (p=0·35) did not 
significantly differ between cases that were and were not part of a genotype cluster (table 2).
Clinical, demographic, and genotypic characteristics did not differ between individuals with 
MDR tuberculosis from TBESC states and those in the rest of the USA during the study 
period, with the exception of ethnic origin. TBESC states had more Hispanic (54 [32%] of 
168 vs 23 [23%] of 100; p<0·0001) and Asian individuals (89 [54%] vs 41 [41%]; p=0·001), 
and fewer black (15 [9%] vs 23 [23%]; p<0·0001) and white individuals (10 [6%] vs 13 
[13%]; p=0·003) than elsewhere in the country. Clinical, demographic, and genotypic 
characteristics did not differ between individuals who did and did not consent to interview 
(data not shown).
In the 92 individuals who consented to an in-depth interview and health-record abstraction, 
eight (9%) developed MDR tuberculosis as a result of transmission in the USA from a 
known source case. 12 (13%) developed MDR disease as part of a transmission event in the 
USA, but no known source case was identified; four were identified as the source case for 
others in the USA. 20 (22%) had imported active tuberculosis. 38 individuals (41%) were 
deemed to have reactivation of tuberculosis, of whom 14 (15%) had a known previous 
episode of tuberculosis outside the USA. Five individuals (5%) had documented treatment 
of a previous episode within the USA, and so were deemed to have relapsed. For nine cases 
(10%), insufficient evidence was available to definitively classify reason for presentation.
Of the 92 individuals who underwent in-depth interview and health-record abstraction, 26 
(28%) had the same genotype as another case of MDR tuberculosis in the same state during 
the surveillance period. Extended typing data were available for comparison for all but two 
pairs of cases. The lack of extended genotyping results in these cases did not affect 
classification of the likelihood of transmission. 14 M tuberculosis clusters were associated 
with US transmission (table 3). 13 (93%) M tuberculosis isolates were of Euro-American 
phylogenetic lineage. Eight clusters (57%) had an identifiable source case, seven (50%) 
were characterised by abuse of illicit drugs or alcohol, two (14%) included confirmed 
transmission to a child,27 and one included transmission across state lines (table 3).8
Overall, people with MDR tuberculosis attributed to transmission in the USA were more 
likely to be male (p<0·0001), have been born in the USA (p<0·0001), be of Hispanic ethnic 
origin (p<0·0001), abuse illicit drugs or alcohol (p<0·0001), and to have an M tuberculosis 
isolate of Euro-American lineage (p<0·0001) than were those who had disease not attributed 
to transmission in the USA (table 4).
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75 (82%) of the 92 individuals who had an in-depth interview and health-record abstraction 
were born outside the USA. The 12 individuals whose disease was linked with transmission 
in the USA but of unknown source were all born outside the USA, and four were identified 
as the source case for others. Nine were diagnosed at least 12 months after US entry, and 
none had a US medical examination on arrival in the country.13 For the eight individuals for 
whom a known source case was identified, only three source cases were born in the USA. 
There were two US-born, paediatric MDR tuberculosis cases included in the study: both 
children were infected by people born outside the USA who had been diagnosed with MDR 
tuberculosis within 12 months of arrival in the USA. Median times between date of US entry 
and diagnosis was 9 years (IQR 6–25) for cases that could be attributed to transmission in 
the USA, and 4 years (1–9) for those that could not be attributed.
Notably, three individuals with extensively drug-resistant tuberculosis (from Kyrgyzstan, 
Nepal, and Russia) were categorised as imported disease, because diagnosis occurred within 
3 months of immigration, their M tuberculosis isolates were non-clustering genotypes, and 
no epidemiological links were identified.
During our study period, we identified 1166 people by contact investigation who were 
exposed to MDR tuberculosis, of whom 353 (30%) were diagnosed with latent tuberculosis 
infection. Although which individuals will go on to develop active MDR tuberculosis is 
unclear, with the assumption that 10% will develop active disease,28 35 new cases of MDR 
tuberculosis could emerge in the USA from our cohort in the absence of efficacious 
preventive treatment.
Panel: Research in context
Systematic review
We searched PubMed with the term: “(tuberculosis OR TB) AND (multidrug resistance 
OR MDR) AND (transmission)” for reports published in any language between Jan 1, 
1965, and April 31, 2013. We identified 630 reports, of which 134 were of peer-reviewed 
studies and contained original data for the epidemiology of drug-resistant tuberculosis, 
such as information about patients and tuberculosis genotype data. In 96 studies, 
information about interpersonal connections or transmission venues (as needed to 
accurately identify transmission events) was not obtained. 35 studies were done in 
outbreak conditions or were narrowly focused on specific groups, such as health-care 
workers, household contacts, people living with HIV infection, prisoners, or miners. Of 
the remaining three population-based studies that investigated transmission of multidrug-
resistant (MDR) tuberculosis, only one was based in the USA: it was done in one state 
more than a decade ago.
Interpretation
As far as we are aware, ours is the largest multicentre, population-based study to include 
detailed information about the potential contributing factors of transmission of MDR 
tuberculosis. We showed that as many as one in every five individuals diagnosed with 
MDR tuberculosis in the USA could be linked to transmission. Evidence-based 
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standardised regimens are urgently needed for people exposed to MDR tuberculosis to 
prevent progression to active disease.
Discussion
In this multicentre, multiyear, population-based study, transmission occurred in roughly a 
fifth of individuals with MDR tuberculosis. Although most people diagnosed with MDR 
tuberculosis were born outside of the USA, some were linked to transmission in the USA, 
including four individuals who were the source of transmission for other cases. A substantial 
proportion of MDR tuberculosis cases represented reactivation of tuberculosis or disease 
acquired outside the USA (20 imported active disease, 14 known previous episode outside 
the USA, five documented treatment of previous episode within the USA; 42%), including 
17 that were diagnosed within 3 months of entry into the USA.
The proportion of MDR tuberculosis cases attributed to transmission within the USA in our 
study (22%) was similar to that in another report of genotyped cases reported in the USA 
(23%),22 but higher than values reported for the state of California (14%14 and 8%18). 
However, in these previous studies,14,18,22 detailed information about interpersonal 
connections between cases was not available, and thus genotyping results alone were used as 
a proxy to determine tuberculosis transmission. In a study following the major outbreak of 
MDR tuberculosis and resurgence of tuberculosis in New York City (NY, USA),29 about 
13% of genotyped MDR tuberculosis cases were epidemiologically linked by medical-
record review and interview of patients, most of whom were exposed to MDR tuberculosis 
long before the study.17
Notably, in our study, half the identified source cases were born outside the USA. This 
finding contrasts with those of other studies, which have suggested that transmission of M 
tuberculosis within a country generally occurs between individuals born there,17,18,22,23 and 
rarely occurs between these people and those born elsewhere.30 Therefore, our findings 
could have important implications for algorithms that assign the likelihood of tuberculosis 
transmission in the USA in the absence of routinely identified epidemiological linkages and 
because important transmission events might be missed in people born elsewhere.31
The large proportion of cases of reactivated disease acquired outside the USA might have 
been prevented had appropriate diagnostic screening and treatment been implemented at or 
before immigration (reducing the potential for transmission in the USA). Our results were 
similar to those of a cross-sectional study of all patients born outside the USA with an M 
tuberculosis isolate genotyped in the USA between 2005 and 2009:23 50% of cases were 
attributable to reactivation of disease acquired elsewhere. Importantly, the primary purpose 
of the present US immigration screening programme is to identify active disease, and not 
latent tuberculosis infection.32 There is no policy to test for latent tuberculosis infection in 
adults born outside the USA before or during the US entry process.32 Moreover, for 
individuals who already live in the USA but were born elsewhere, present guidelines33 
recommend testing for latent tuberculosis infection only for those who have been in the 
USA for less than 5 years.
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More importantly, prevention of transmission and progression to active disease is more 
challenging after exposure to MDR M tuberculosis than after exposure to drug-susceptible 
M tuberculosis. The principal strategy to interrupt tuberculosis transmission and reduce the 
likelihood of remote reactivation of disease is to use treatment for latent infection. Several 
treatment regimens are available for people who have latent tuberculosis and are exposed to 
drug-susceptible M tuberculosis, including a once weekly, 12-dose regimen.34 However, 
because all isolates of MDR M tuberculosis have resistance to isoniazid and rifampicin, 
most evidence-based regimens are not appropriate for individuals exposed to MDR 
tuberculosis. The American Thoracic Society and CDC recommend that immunocompetent 
people exposed to MDR tuberculosis be followed up for 24 months, irrespective of 
treatment.33 When treatment is given, a two-drug regimen taken for 6–12 months is 
recommended if bacteria from the index case are known to be susceptible to pyrazinamide 
and ethambutol, or pyrazinamide and a fluoroquinolone.33 Unfortunately both pyrazinamide 
regimens have high toxicity;35,36 thus, careful follow-up without any treatment is a 
justifiable option for immunocompetent individuals. Therefore, the decision to treat latent 
tuberculosis infection as a result of exposure to MDR disease—and how to go about it—
remains highly controversial.
As yet, no randomised controlled trials of the efficacy of recommended treatment 
combinations for latent MDR tuberculosis infection have been reported.37 Several approvals 
for new antituberculosis drugs are imminent, including some with early bactericidal 
activity,38,39 but these drugs might not be available for routine clinical care for several 
years. Because these drugs are being developed primarily to shorten treatment and improve 
clinical outcomes, whether they will be effective in prophylaxis or whether they should be 
used at all for latent infection to protect against potential acquired drug resistance is 
unknown.40,41
During our study, contact investigation identified 1166 individuals who were exposed to 
MDR tuberculosis, including 353 (30%) diagnosed with latent tuberculosis infection. 
Although which individuals will go on to develop active disease is unclear, 35 new cases 
will potentially emerge in the future in the USA from this cohort without efficacious 
preventive treatment.
Our study was one of the largest population-based studies of MDR tuberculosis transmission 
(panel), and we included all genotyped cases reported in eight states during the surveillance 
period, but only about 60% of eligible cases were available for in-depth interview. 
Genotypic and epidemiological linkages based on both interview and public health records 
provided a strong assessment of transmission between enrolled individuals, but because not 
all isolates received all three genotyping methods (ie, spoligotyping, 24-locus MIRU-VNTR 
and IS6110-RFLP), some clusters could possibly be divided into small subsets. Therefore, 
we might have underestimated transmission. Moreover, not all individuals with MDR 
tuberculosis, including those in adjacent states, were interviewed, so we might have 
underestimated the proportion of cases with epidemiological linkages and therefore 
transmission between states. Additionally, because MDR tuberculosis was a rare event, our 
sample size was small and cell size could affect some statistical inferences.
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In conclusion, although roughly four-fifths of individuals with MDR tuberculosis included 
in our study were born outside the USA, a fifth could be linked to transmission after 
immigration. These findings, in addition to the substantial proportion of cases that were 
reactivation of MDR disease or disease acquired outside the USA, further emphasise the 
immediate need for evidence-based, standardised regimens to prevent transmission of MDR 
tuberculosis and progression of active disease.
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Table 1
Categories of reason for disease occurrence
Criteria
Definite transmission Documented transmission in the USA from a known source; no previous history of latent infection 
or active disease
Possible transmission Putative transmission in the USA from an unknown source; no previous history of latent infection 
or active disease
Imported active tuberculosis Foreign-born individual who was diagnosed with MDR tuberculosis within 3 months of entry into 
the USA, or who had symptom onset before entry and a subsequent MDR tuberculosis isolate 
obtained in the USA
Reactivation of remotely acquired 
tuberculosis infection*
Individuals with non-clustered genotypes (ie, unique) reported in the same state with no 
epidemiological link
Known tuberculosis episode outside the 
USA
Foreign-born individual who had no evidence of active disease at entry into the USA and no 
evidence of transmission of MDR disease within the USA; documented tuberculosis treatment 
outside of the USA; subsequent relapse after more than 3 months in the USA
Known relapse of MDR tuberculosis 
within the USA
Treatment of a previous episode within the USA; no evidence of exposure to another case
Unable to classify Insufficient evidence to classify into one of the other categories
MDR=multidrug-resistant.
*
Infection acquired in the distant past.
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Table 2
Characteristics of patients with multidrug-resistant tuberculosis for whom genotyped isolates were available
Part of genotype cluster Total (n=168) Relative risk (95% CI)
Yes (n=26) No (n=142)
Sex*
Male 19 (76%) 61 (45%) 80 3·2 (1·4–7·7)
Female 6 (24%) 76 (55%) 82 ··
Hispanic ethnic origin
Yes 18 (69%) 36 (25%) 54 4·8 (2·2–10·2)
No 8 (31%) 106 (75%) 114 ··
Country of birth
USA 4 (15%) 20 (14%) 24 1·1 (0·4–2·9)
Other 22 (85%) 122 (86%) 144 ··
Homelessness within the past 12 months
Yes 4 (15%) 8 (6%) 12 2·4 (1·0–5·7)
No 22 (85%) 134 (94%) 156 ··
Substance abuse within the past 12 months
Yes 6 (23%) 18 (13%) 24 1·8 (0·8–4·0)
No 20 (77%) 124 (87%) 144 ··
In prison at time of diagnosis
Yes 4 (15%) 3 (2%) 7 4·2 (2·0–8·9)
No 22 (85%) 139 (98%) 161 ··
Pulmonary involvement
Yes 23 (88%) 131 (92%) 154 0·7 (0·2–2·0)
No 3 (12%) 11 (8%) 14 ··
Positive sputum smear
Yes 15 (58%) 79 (56%) 94 1·1 (0·5–2·2)
No 11 (42%) 63 (44%) 74 ··
Cavitary chest radiograph†
Yes 10 (38%) 46 (33%) 56 1·2 (0·6–2·5)
No 16 (62%) 95 (67%) 111 ··
Previous tuberculosis diagnosis
Yes 2 (8%) 30 (21%) 32 0·3 (0·1–1·4)
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Part of genotype cluster Total (n=168) Relative risk (95% CI)
Yes (n=26) No (n=142)
No 24 (92%) 112 (79%) 136 ··
Euro-American Mycobacterium tuberculosis lineage
Yes 19 (73%) 57 (40%) 76 3·3 (1·5–7·4)
No 7 (27%) 85 (60%) 92 ··
*
Data not reported as part of routine surveillance for six individuals: one in genotype cluster and five not in genotype cluster.
†
Data not reported as part of routine surveillance for one individual who was not in genotype cluster.
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Table 4
Characteristics of patients with multidrug-resistant tuberculosis who consented to an in-depth interview
Disease linked with transmission in the USA Total (n=92) Relative risk (95% CI)
Yes (n=20) No (n=72)
Sex
Male 15 (75%) 29 (40%) 44 3·1 (1·2–8·3)
Female 5 (25%) 43 (60%) 48 ··
Age (years)*
0–4 1 (5%) 0 1 ··
5–14 1 (5%) 0 1 ··
15–24 2 (10%) 15 (21%) 17 ··
25–44 7 (35%) 34 (47%) 41 ··
45–64 9 (45%) 21 (29%) 30 ··
≥65 0 2 (3%) 2 ··
Aged <25 years
Yes 4 (20%) 15 (21%) 19 1·0 (0·4–2·5)
No 16 (80%) 57 (79%) 73 ··
Ethnic origin†
Asian 0 38 (53%) 38 ··
Black 2 (10%) 7 (10%) 9 ··
Hispanic 17 (85%) 20 (28%) 37 ··
White 1 (5%) 7 (10%) 8 ··
Hispanic ethnic origin
Yes 17 (85%) 20 (28%) 37 8·4 (2·7–26·7)
No 3 (15%) 52 (72%) 55 ··
Country of birth
USA 8 (40%) 9 (13%) 17 2·9 (1·4–6·1)
Other 12 (60%) 63 (88%) 75 ··
Homelessness within the past 12 months
Yes 3 (15%) 4 (6%) 7 2·1 (0·8–5·6)
No 17 (85%) 68 (94%) 85 ··
Abuse of alcohol or illicit drugs within the past 12 months
Yes 9 (45%) 6 (8%) 15 4·2 (2·1–8·3)
No 11 (55%) 66 (92%) 77 ··
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Disease linked with transmission in the USA Total (n=92) Relative risk (95% CI)
Yes (n=20) No (n=72)
In prison at time of diagnosis
Yes 1 (5%) 1 (1%) 2 2·3 (0·6–10·0)
No 19 (95%) 71 (99%) 90 ··
Resident of a long-term care facility at time of diagnosis
Yes 1 (5%) 1 (1%) 2 2·3 (0·6–10·0)
No 19 (95%) 71 (99%) 90 ··
Reported HIV status
Positive 2 (10%) 2 (3%) 4 2·4 (0·8–7·1)
Not positive 18 (90%) 70 (97%) 88 ··
Clinical presentation‡
Pulmonary only 16 (80%) 66 (92%) 82 ··
Extrapulmonary only 2 (10%) 2 (3%) 4 ··
Both pulmonary and extrapulmonary 2 (10%) 4 (6%) 6 ··
Pulmonary involvement
Yes 18 (90%) 70 (97%) 88 0·4 (0·1–1·2)
No 2 (10%) 2 (3%) 4 ··
Extent of disease§
Extensive 11 (55%) 40 (56%) 51 ··
Moderate 0 5 (7%) 5 ··
Non-extensive 9 (45%) 26 (36%) 35 ··
Unknown 0 1 (1%) 1 ··
Positive sputum smear
Yes 13 (65%) 45 (63%) 58 1·1 (0·5–2·5)
No 7 (35%) 27 (38%) 34 ··
Cavitary chest radiograph
Yes 7 (35%) 32 (44%) 39 0·7 (0·3–1·7)
No 13 (65%) 40 (56%) 53 ··
Previous tuberculosis diagnosis
Yes 0 16 (22%) 16 ··
No 20 (100%) 56 (78%) 76 ··
Mycobacterium tuberculosis spoligotype-based lineage¶
East African Indian 0 2 (3%) 2 ··
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Disease linked with transmission in the USA Total (n=92) Relative risk (95% CI)
Yes (n=20) No (n=72)
East Asian 1 (5%) 29 (40%) 30 ··
Euro-American 19 (95%) 29 (40%) 48 ··
Indo-Oceanic 0 11 (15%) 11 ··
Mycobacterium africanum 0 1 (1%) 1 ··
Mycobacterium bovis 0 0 0 ··
Euro-American lineage ··
Yes 19 (95%) 29 (40%) 48 17·4 (2·4–124·7)
No 1 (5%) 43 (60%) 44 ··








χ2 test: p=0·57; extensive disease when positive sputum smear and cavitary chest radiograph, positive sputum smear and bilateral infiltrates, or 
miliary tuberculosis; non-extensive when negative sputum smear and non-cavitary chest radiograph; moderate for all other clinical presentations.
¶
χ2 test: p<0·0001.
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